EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 152 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 0.87 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $758,000 | -34.2% | 9,608 | -30.8% | 0.03% | -39.3% |
| Q1 2017 | $1,152,000 | +59.8% | 13,892 | +52.9% | 0.06% | -3.4% |
| Q4 2016 | $721,000 | +235.3% | 9,083 | +274.9% | 0.06% | +286.7% |
| Q4 2015 | $215,000 | -43.4% | 2,423 | -52.8% | 0.02% | -34.8% |
| Q3 2015 | $380,000 | -47.0% | 5,138 | -42.0% | 0.02% | -42.5% |
| Q2 2015 | $717,000 | +116.6% | 8,862 | +12.2% | 0.04% | +100.0% |
| Q1 2015 | $331,000 | – | 7,896 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Hudson Executive Capital LP | 1,323,794 | $79,534,000 | 3.54% |
| Park West Asset Management LLC | 1,171,880 | $70,406,000 | 2.96% |
| Matarin Capital Management, LLC | 170,008 | $10,214,000 | 0.98% |
| Smith, Graham & Co., Investment Advisors, LP | 140,014 | $8,412,000 | 0.82% |
| Capital Impact Advisors, LLC | 33,725 | $2,026,000 | 0.71% |
| U S GLOBAL INVESTORS INC | 18,800 | $1,130,000 | 0.51% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 187,989 | $11,294,000 | 0.37% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,442,000 | 0.34% |
| GLOBEFLEX CAPITAL L P | 18,751 | $1,127,000 | 0.21% |
| Foundry Partners, LLC | 70,357 | $4,227,000 | 0.16% |